A clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, with lead programs in idiopathic pulmonary fibrosis, hepatocellular carcinoma, and other conditions with significant unmet medical need.